Nicole Rivera, PA
Surgical · Washington, DCNPI 1336732601
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,311 of the $2,118 with a category attached, or 61.9%. 17 manufacturers reported payments, led by Medical Device Business Services, Inc. at 42.0% of the total. Reporting peaked in 2022 at $906 and has fallen 64.9% since, to $319 in 2024. Among surgical clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $64.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$889
- AstraZeneca$328
- Foundation Medicine, Inc.$119
- Melinta Therapeutics, LLC$116
- E.r. Squibb & Sons, L.L.C.$116
- Bayer$114
- plus $436 from 11 others
What the payments were for
- Speaking & faculty fees$1196%
- Travel & lodging$68832%
- Food & beverage$1,31162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 7 | $889 |
| AstraZeneca | 6 | $328 |
| Foundation Medicine, Inc. | 1 | $119 |
| Melinta Therapeutics, LLC | 1 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $116 |
| Bayer | 1 | $114 |
| Davol Inc. | 1 | $94 |
| Johnson & Johnson | 1 | $67 |
| Amarin Pharma, Inc. | 3 | $55 |
| GSK | 3 | $49 |
| Revance Therapeutics, Inc. | 1 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Werfen USA LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$246
- FOUNDATIONONE LIQUID CDX$119
- Rezzayo$116
- Reblozyl$116
- Nubeqa$114
How this compares
$2,118 in reported general payments places this provider in the 95th percentile of 67 surgical providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 17 | $206 |
Paid to pharmacies, not to this prescriber.
Other surgical in Washington
- Nirali PatelWashington$4K
- Kelly DonahueWashington$2K
- Bryn KellyWashington$2K
- Hannah KobettWashington$2K
- Morgan KrausWashington$2K
- Eleni NeelWashington$2K
- Ashley LeclareWashington$2K
- Haleigh KleinmanWashington$1K
- Katharine EndresWashington$1K
- Ashleigh RushWashington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.